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With the emergence of SARS-CoV-2 and its rapid spread, concerns regarding its eﬀects on pregnancy outcomes have been growing.
We reviewed 245 pregnancies complicated by maternal SARS-CoV-2 infection across 48 studies listed on PubMed and MedRxiv.
The most common clinical presentations were fever (55.9%), cough (36.3%), fatigue (11.4%), and dyspnea (12.7%). Only 4.1% of
patients developed respiratory distress. Of all patients, 89.0% delivered via cesarean section (n = 201), with a 33.3% rate of
gestational complications, a 35.3% rate of preterm delivery, and a concerning 2.5% rate of stillbirth delivery or neonatal death.
Among those tested, 6.45% of newborns were reported positive for SARS-CoV-2 infection. Relative to known viral infections,
the prognosis for pregnant women with SARS-CoV-2 is good, even in the absence of speciﬁc antiviral treatment. However,
neonates and acute patients, especially those with gestational or preexisting comorbidities, must be actively managed to prevent
the severe outcomes being increasingly reported in the literature.

1. Introduction
The emergence of SARS-CoV-2 as a novel infection in
late December 2019 poses unique challenges to healthcare
systems and practitioners. Chief among them is the management for pregnant women who are infected with SARS-CoV2. Pregnant women are prone to a range of fetal and maternal
complications that could impact the outcome of any concurrent infection [1]. The ﬁrst trimester bears a major risk for
miscarriage and fetal developmental abnormalities. The late
second and third trimesters carry an increased likelihood
for the development of maternal conditions, such as gestational diabetes and hypertensive disorders, which contribute
to maternal morbidity and premature birth.

Cells at the maternal-fetal interface play crucial roles in
fetal development and regulation of the maternal immune
response [2]. Viral infections can interfere with the function
of these cells and ultimately impair placental function [2].
Over the years, many studies have investigated the maternal
and neonatal outcomes in the setting of several recent epidemics such as inﬂuenza A (H1N1), SARS-CoV, Middle East
Respiratory Syndrome (MERS), and Respiratory Syncytial
Virus (RSV). A case-control study (deaths and recovered)
conducted in Brazil on women infected with inﬂuenza A
(H1N1) reported a higher rate of fetal deaths and preterm
births among women who eventually died as a result of the
infection, compared to women who had recovered. Further,
recovered cases had more favorable neonatal outcomes

2
following discharge [3]. The authors reported that early
antiviral treatment (48 to 72 hours of symptom onset) is a
protective factor, whereas having a previous visit to a healthcare provider for an inﬂuenza episode prior to hospital
admission was a risk factor for death [3]. A systematic review
conducted in 2017 on maternal inﬂuenza infection reported
preterm birth rates (prior to 37 weeks of gestation) of
11.4%, 7.7%, 7.1%, and 6.3% in the United States, Canada,
the United Kingdom, and Norway, respectively [4]. In pregnancies aﬀected by respiratory syncytial virus (RSV), the rate
of preterm births was reported as 29%, which is comparable
to a rate of 13% for preterm births in noninfected pregnant
women [5]. Among infants born to mothers with postpartum
RSV infection, 57% were infected with RSV [5]. A systematic
review published in 2020 compared maternal and neonatal
outcomes among patients infected with either SARS-CoV,
SARS-CoV-2, or MERS. When compared to SARS-CoV
and MERS, SARS-CoV-2 was associated with the highest rate
of preterm birth, fetal distress, perinatal death, and C-section
deliveries [6]. Additionally, no Apgar scores < 7 were reported
in any of the SARS-CoV and MERS cases, whereas 2.4% of
SARS-CoV-2 cases had Apgar scores < 7 [6]. There was no
evidence of vertical transmission in any of the three infections [6].
It is well known that infectious pneumonia is a common
cause of morbidity and mortality in pregnant women due to
several physiological factors such as lower lung volumes and
increased oxygen consumption [7, 8]. Indeed, a quarter of
pregnancies complicated by pneumonia are estimated to
require critical care hospitalization and ventilation support
[9]. Pregnancy-induced changes to immunity, such as
reduction in cell-mediated cytotoxicity, diminished lymphokine response, and reduction in lymphocyte proliferative
response, further add to the prognostic picture of pneumonia
in pregnant women [8]. Hence, the advent of the SARSCoV-2 pandemic could raise new questions about perinatal
and obstetric management. Here, we review 245 pregnancies
reported in the literature across 48 studies.

2. Methods
We searched PubMed using the All Fields and MeSH tags
for the terms “coronavirus,” “ncov,” “cov,” “2019-nCoV,”
“COVID-19,” “SARS-CoV-2,” “pregnancy,” “complications,” “miscarriage,” and “anomalies.” We limited our
search to all published studies between December 20, 2019,
and July 30, 2020. Our search retrieved 221 papers. We
carried out the same search on MedRxiv, which yielded 10
results. We screened the papers through Covidence. We
excluded reviews, meta-reviews, letters to the editor, and
guidelines that are speciﬁc to a region. We also excluded
articles in languages besides English. We then reviewed the
results for relevance and included the articles that reported
on SARS-CoV-2 in pregnant patients. This search strategy
resulted in 48 case reports and articles from the primary
literature that we included in this review (Figure 1). We
extracted all information about patient characteristics, symptoms, laboratory results, and imaging studies. We also gathered the relevant data about the pregnancy course such as
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delivery method, gestational complications, and neonatal
outcomes. The data from each article were recorded at the
level of individual patients and combined across studies for
calculating the frequency of the outcomes in all patients.

3. Results
The papers we reviewed consist of 245 patients, all of whom
are pregnant women with a conﬁrmed diagnosis of SARSCoV-2, with a mean maternal age of 28.3 (range of 24-43
years old, n = 241) and a mean gestational age (GA) of
35.67 weeks (range 18-41 weeks, n = 119). Results from
individual studies are described and summarized in Supplementay Tables 1 and 2.
3.1. Maternal Symptoms. With regard to prepartum symptoms, the most common symptoms were fever (55.9%)
followed by cough (36.3%), dyspnea (12.7%), and fatigue
(11.4%). Less common symptoms included diarrhea and
other gastrointestinal (GI) symptoms, sore throat, nasal
congestion and rhinorrhea, muscle aches, rash, headache,
hoarseness, myalgia, high blood pressure (BP), tachycardia,
and cholecystitis. Only 4.5% of all patients were asymptomatic prior to delivery. Several patients who were asymptomatic prior to delivery became symptomatic postpartum,
requiring ICU admission.
The majority of the studies only included patients in the
third trimester with the exception of eight studies which also
included patients in the ﬁrst and second trimesters. Most of
these studies reported the number of patients experiencing
each symptom without specifying the GA, so it is diﬃcult
to determine whether patients in earlier trimesters diﬀered
in their clinical presentations from those in later trimesters.
Liu and colleagues reported 15 patients who ranged in GA
from 12 to 38 weeks, but it was not clear whether the patients
in the earlier trimester experienced diﬀerent symptoms or
complications [10]. Nie included 33 patients in total which
ranged in GA from 24 to 36 weeks [11]. No ICU admissions
or mortalities were reported, and the study concluded that
pregnant women were not at an increased risk for severe
illness or mortality. Based on the ﬁndings reported by Liu
et al. and Nie, patients’ clinical presentations do not appear
to diﬀer based on the GA of pregnancy.
Among the reported postpartum symptoms, the most
common one was fever (13.5%). In one patient who was
admitted with worsening hypertension and a history of
diabetes mellitus (DM) and asthma, postpartum symptoms
included low oxygen saturation, tachycardia, dyspnea, diaphoresis, and cough that progressed to respiratory failure
[12]. Gidlöf et al. also reported low-oxygen saturation postpartum [13]. Among 13 patients, Liu and colleagues reported
that one patient developed Multi Organ Dysfunction
Syndrome (MODS) including Acute Respiratory Distress
Syndrome (ARDS) [14]. Thus, out of 245 pregnant women
with SARS-CoV-2, 10 (4.1%) developed respiratory distress.
3.2. Laboratory Findings. The most common laboratory
abnormalities seen in pregnant women infected with SARSCoV-2 were elevated C-reactive protein (CRP), neutrophilia,

Identiﬁcation
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Records identiﬁed through
database searching
(n = 221)

Additional records identiﬁed
through other sources
(n = 10)

Eligibility

Screening

Records after duplicates removed
(n = 231)

Records screened
(n = 220)

Excluded due to irrelevance
or scope (n = 110)

Full-text articles assessed
for eligibility
(n = 110)

Articles excluded due to
review status (n = 45) or
large sample size (n = 17)

Included

Studies included in systemic analysis
(n = 48)

Figure 1: Search strategy ﬂowchart.

and leukocytosis. In the studies that reported laboratory ﬁndings, 147 pregnant women were included, and among them,
49% had elevated CRP, 31.3% had lymphopenia, 28.6% had
neutrophilia, and 12.2% had leukocytosis. Other laboratory
abnormalities included thrombocytopenia, elevated D-dimer,
abnormal liver enzymes, decreased albumin, low hemoglobin
(Hb), elevated alkaline phosphate, eosinopenia, elevated uric
acid, elevated ferritin, pancytopenia, prolonged activated partial thromboplastin time (APTT), low ﬁbrinogen, and progressive coagulopathy.
3.3. Chest X-Ray (CXR). Most studies reported imaging
abnormalities in either chest X-ray (CXR), computed tomography (CT), or both. In terms of CXR, Li et al. (n = 1)
reported scattered multiple patchy inﬁltrates in both lungs,
and Lee et al. (n = 1) reported left lower/middle lobe consolidation and increased vascular marking, while Breslin et al.
(n = 1) reported mild pulmonary vascular congestion with
no consolidation or eﬀusion [12, 15, 16]. All three women
were of similar GA (mean 36 weeks).
3.4. Computed Tomography (CT) Scan. Typical signs of viral
pneumonia were frequently reported, with most patients
having bilateral lung involvement. CT ﬁndings did not show
signs of worsening pneumonia postpartum. However, with
disease progression, Zhu et al. reported that lesions merged

into strips and Liu et al. observed a paving pattern and consolidation [10, 17]. Ground glass opacities (GGO) were
reported in the majority of studies. Mixed GGO with consolidation were more common among pregnant SARS-CoV-2
patients in comparison to nonpregnant SARS-CoV-2
patients [10]. Lee and colleagues also reported GGO with
consolidation [15]. In addition to multiple bilateral consolidations, bilateral pleural eﬀusion were observed [18]. Given
the prevalence of respiratory symptoms in pregnant women
infected with SARS-CoV-2, lung ultrasound is a valuable tool
in conﬁrming diagnosis of SARS-CoV-2 infection as well as
monitoring disease progression [19]. Lung ultrasound eliminates the radiation risk and avoids the incidence of falsenegative results associated with other diagnostic tests. As
outlined by Moro and colleagues, speciﬁc guidelines can be
followed when performing lung ultrasound for pregnant
women infected with SARS-CoV-2 [19].
3.5. Maternal and Obstetric Complications. There have been
several reports of uncomplicated term delivery in SARSCoV-2-positive women [15, 20]. Of 201 deliveries reported,
182 were performed as C-sections. The rate of C-sections is
thus 89% of all deliveries, signiﬁcantly higher than the
expected rate of approximately 15% for pregnancies in
the general population [21, 22]. This rate of C-section is
also higher than that in pregnancies complicated by viral
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Inﬂuenza infection, where the likelihood of C-section did not
increase relative to the general population [23].
Several case reports highlight the frequency of C-section
deliveries compared to vaginal deliveries, whether in healthyappearing patients or patients presenting with fever [17, 24].
The indications for C-section varied and were not consistently
reported across studies. In certain hospitals, the choice of
C-section was determined by obstetric factors [25]. In
others, C-section was performed proactively due to
maternal SARS-CoV-2 infection. Presumably, C-sections
minimize cross-infection and reduce maternal exertion
during labor, as per certain recommendations [26]. Due
to the uneven distribution of C-sections as opposed to
vaginal delivery, it is not possible to comment on diﬀerences in neonatal and maternal outcomes between vaginal
delivery and C-sections in SARS-CoV-2 pregnancies.
Importantly, there are no contraindications for vaginal
delivery as evidenced by the uncomplicated vaginal delivery in at least ﬁve patients [27, 28]. It is not clear from
this review if the high cesarean section rate is warranted.
Out of 245 patients reviewed, we looked at the following
gestational complications: gestational diabetes, preeclampsia/gestational hypertension, and placental complications,
such as premature rupture of membrane or placenta previa.
The combined rate of complications was at 33.3%, consisting
of gestational diabetes (6.9%), preeclampsia/gestational
hypertension (6.1%), and placental complications (6.5%).
There were at least 34 patients (13.8%) with other overlapping complications, including 9 cases of intrauterine fetal
demise in the second and third trimesters (3.6%), 8 cases of
maternal mortality (3.2%), and 7 cases of maternal hypoxia
(2.8%). It is worth noting that 7 out of the eight cases of
maternal mortality occurred among patients within the same
study in the same hospital, and thus, the rate of maternal
mortality may seem falsely elevated [29].
3.6. Fetal and Neonatal Outcomes. The literature reviewed
reported information for 201 newborns. Out of 201 neonates,
71 (35.3%) were delivered preterm, before 36 weeks of gestation. Again, it is not consistently clear whether early delivery
was induced in light of obstetric indications or maternal
SARS-CoV-2 infection. The average Apgar score was 6.49
at 1 minute and 8.98 at 5 minutes.
Seven fetuses (2.8%) exhibited fetal distress, which was
the indication for preterm delivery in some cases. Postnatally, the rate of abnormal respiratory ﬁndings among the
neonates was at 4.4%, divided as follows: 6 neonates had
shortness of birth, 2 had pneumonia-like presentation on
imaging, and one had respiratory distress including one
case of ARDS. All cases resolved with antibiotics without
complication.
Of the 201 fetuses, ﬁve (2.5%) had very poor outcomes:
two deliveries resulted in stillbirth, and three neonates passed
away soon after delivery [14, 17, 29, 30]. One neonate developed refractory shock and multiple organ failure and passed
on day 8 of life, while the other two were delivered by a
mother who developed hypoxia in late pregnancy [17, 29].
Although no fetus is thought to have died as a result of fetal
infection, Baud et al. suggest that placental inﬂammation in
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the setting of the virus contributes to fetal distress, even when
the fetal is not infected [30].
3.7. Vertical Transmission and Breastfeeding. Notably, several
case studies have ruled out vertical transmission of SARSCoV-2. This is largely supported by our review. Out of the
neonates tested for SARS-CoV-2 infection (n = 93), 6 tested
positive for the infection through nasopharyngeal swab
(6.45%). All cases in question raise concerns about potential
vertical transmission, since the mother and the obstetric
team practiced protection and isolation measures to prevent
infection during the delivery process and immediately
afterwards [11, 18]. However, because of the asymptomatic
presentation of many infected individuals, it is possible that
the neonates had acquired SARS-Cov-2 in the hospital or in
their home environment after birth.
Certain studies went beyond testing the newborn for
evidence of vertical transmission. For instance, Gidlöf et al.
tested breast milk and maternal vaginal secretion of a
SARS-CoV-2-positive mother [13]. Li et al. tested the breast
milk, amniotic ﬂuid, umbilical cord blood and placenta,
maternal serum, urine, and feces of a SARS-CoV-2-positive
mother [14]. Five out of 7 placentas tested (71.4%) were positive for SARS-CoV-2, while 2 out of 13 tissue samples tested
(15.3%) were positive.
One out of 6 breast milk samples tested (16.6%) was positive for SARS-CoV-2. Interestingly, SARS-CoV-2 IgG and
IgA were detected in a placental tissue and breast milk sample, respectively [31]. These results, in addition to several
guidelines such as those published by the ACOG and the
RCOG, converge on the idea that SARS-CoV-2 is not carried
through breast milk [32, 33]. However, the underlying risk of
neonatal exposure to maternal respiratory droplets during
the breastfeeding process persists. Overall, the many beneﬁts
of breastfeeding do make breastfeeding safe, as long as SARSCoV-2-positive mothers take reasonable precautions while in
close contact with the newborn.

4. Conclusions
According to Liu et al., pregnancy and delivery did not aggravate the severity of SARS-CoV-2 in the patients studied [10].
However, as one expects, the variability in the severity of
infection and pneumonia presentation in diﬀerent patients
makes such a statement diﬃcult to prove.
Pregnancy, in particular, the third trimester, is associated
with changes in lung physiology, such as decreases in ERV
and FRC volumes, and increases in respiratory resistance
[34]. A prime example is the fact that pregnant women
infected with the H1N1 virus during the 2009 epidemic were
at a signiﬁcantly higher risk of complications and hospitalization than nonpregnant women [35, 36]. Hence, an increased
rate of respiratory complications, in addition to maternal
and neonatal complications, could be expected in pregnant
patients with SARS-CoV-2 infection. The absence of widespread respiratory complications is surprising and suggests
that a larger number of patients will help better understand the natural history of SARS-CoV-2 infections during
pregnancy.
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It is certainly true that, at least from the available reports,
the mortality risk in SARS-CoV-2 pregnant women is low.
There exists only eight cases of maternal mortality and
ten other cases of patients developing respiratory distress
[12–14]. At the time of writing, there exists only reports of
severe complications during late pregnancy and no reports
of termination due to early congenital defects. In the 20022004 SARS epidemic, miscarriage rates were reported to be
as high as 50% for infected women in the ﬁrst trimester
[37]. Similarly, infection with the seasonal inﬂuenza virus is
associated with higher miscarriage and maternal mortality
rates than the noninfected population [1, 35]. It should be
noted however that miscarriage could be due to the maternal
response to the infection, rather than a direct placental eﬀect
induced by the infection [38]. In the case of SARS-CoV-2, it
is highly likely that the higher rate of stillbirths and IUFD
cases could be attributed to fever. In contrast to these viral
infections, the outcomes for SARS-CoV-2-infected pregnant
women in the ﬁrst trimester are reassuring.
With regard to fetal and neonatal outcomes, pneumonias
during pregnancies are associated with an increased risk of
preterm birth compared to the general population [39].
Our ﬁndings are consistent with this observation. Fortunately, premature neonates fared well and had comparable
Apgar scores to the full-term neonates included in the analysis. Unfortunately, the rate of stillbirth and neonatal death
among this group was 2.5%, signiﬁcantly higher than the rate
among the general population. Intrauterine growth restriction (IUGR) was an expected ﬁnding in this group due to
its prevalence in prior SARS infections during pregnancy
[40]. However, there was little reporting on IUGR among
fetuses in SARS-CoV-2-positive pregnancies.
Although our review includes a high number of patients,
it is limited by the heterogeneity of the studies’ primary outcomes and reporting methods. Secondly, the availability of
few reports of severe outcomes makes it diﬃcult to explain
the pathophysiology of stillbirths and maternal morbidity
in the setting of SARS-CoV-2. Thirdly, the small sample
scope of placental tissue and breast milk samples challenges
the assumed null risk of transmission between the mother
and the baby. As more case reports become available, subgroup analyses will enable stronger understanding of the
impact of the virus on maternal and fetal health.
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